PMV Pharma Q2 EPS $(0.02) Beats $(0.33) Estimate
Portfolio Pulse from Benzinga Newsdesk
PMV Pharma (NASDAQ:PMVP) reported a Q2 EPS loss of $(0.02), significantly beating the analyst consensus estimate of $(0.33) and showing a substantial improvement from the $(0.38) loss per share in the same period last year.
August 08, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PMV Pharma reported a Q2 EPS loss of $(0.02), which is significantly better than the analyst estimate of $(0.33) and an improvement from last year's $(0.38) loss per share.
The significant beat on EPS estimates and the improvement from last year's loss per share are likely to positively impact PMV Pharma's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100